Table 1 Sociodemographic and clinical characteristics

Male/Female

6/12

12/6

0.11

Age, yr, mean ± SD

38.1 ± 13.8

40.0 ± 11.8

0.60

Weight, kg, mean ± SD

63.5 ± 16.7

70.9 ± 15.1

0.15

Height, cm, mean ± SD

160.8 ± 8.0

164.7 ± 9.8

0.18

BMI, kg/m², mean ± SD

24.4 ± 5.5

26.3 ± 5.4

0.29

 Total number of ECT treatments, mean ± SD

7.2 ± 3.2

7.6 ± 2.8

0.68

 Seizure threshold, mC, mean ± SD

100.0 ± 31.1

96.8 ± 50.5

0.81

 Stimulus dose of the last treatment, mC, mean ± SD

306.7 ± 176.2

251.6 ± 136.1

0.30

 Seizure adequacy, %, mean ± SD

48.0 ± 28.7

45.2 ± 28.6

0.40

 ASA class 1–2/ASA class 3

16/4

18/2

0.66

 Predicted blood level of propofol, μg/mL, mean ± SD

3.16 ± 0.86

2.71 ± 0.78

<  0.001

 Total dose of propofol, mg/kg, mean ± SD

1.31 ± 0.60

1.06 ± 0.22

<  0.001

 Succinylcholine, mg/kg, mean ± SD

1.10 ± 0.30

1.20 ± 0.28

0.002

 ASTI, min, mean ± SD

4.55 ± 1.68

3.63 ± 1.29

<  0.001

 Recovery time, min, mean ± SD

7.98 ± 8.83

5.84 ± 4.76

0.015

 Schizophrenia

8 (40%)

8 (40%)

1

 Bipolar disorder

5 (25%)

7 (35%)

0.49

 Major depressive disorder

7 (35%)

5 (25%)

0.49

 Antipsychotics

17 (85%)

15 (75%)

0.70

 Antidepressants

9 (45%)

8 (40%)

0.75

 Benzodiazepines

8 (40%)

8 (40%)

1

 CGI-S

5.39 ± 0.92

5.22 ± 0.73

0.55

 CGI-I

4.78 ± 0.88

4.78 ± 0.94

1

 MoCA

18.2 ± 9.7

20.2 ± 8.6

0.52